| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TD Cowen analyst Yaron Werber maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $800 to $1146.
RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $850 to $860.
Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target ...
HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $774...
argenx (NASDAQ:ARGX) reported quarterly earnings of $5.18 per share which beat the analyst consensus estimate of $4.30 by 20.44...
argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from...
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis ...